T. Rowe Price Investment Management, Inc.

Position in TNGX — Tango Therapeutics, Inc.

CIK 1897612 BALTIMORE, MD

Position in TNGX

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$9,205,113

+$5,251,666 QoQ

Shares Held

440,015

-1.4% QoQ

Ownership

0.304%

of shares outstanding

% of Portfolio

0.01%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Dec 2023

10 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

T. Rowe Price Investment Management, Inc. holds $11,176,949,825 across 48 Biotechnology names. TNGX ranks #41 (0.1% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ALNY	Alnylam Pharmaceuticals, Inc.	5,193,324	$1,718,315,111
2	ASND	Ascendis Pharma A/S	6,162,042	$1,409,443,866
3	CYTK	Cytokinetics Inc	17,523,840	$1,154,996,294
4	APGE	Apogee Therapeutics, Inc.	10,300,984	$867,033,823
5	PCVX	Vaxcyte, Inc.	12,126,017	$704,642,847
6	DYN	Dyne Therapeutics, Inc.	30,785,801	$558,146,572
7	BNTX	BioNTech SE	5,856,073	$520,487,768
8	IONS	Ionis Pharmaceuticals Inc	6,159,027	$462,481,337

10 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$9,205,113	440,015	-1.4%	Shares	Sole	2026-05-15
2025-12-31	$3,953,447	446,213	-87.3%	Shares	Sole	2026-02-19
2025-09-30	$29,621,415	3,526,359	+11.3%	Shares	Sole	2025-11-14
2025-06-30	$16,226,437	3,169,226	-4.3%	Shares	Sole	2025-08-14
2025-03-31	$4,538,055	3,312,449	-1.0%	Shares	Sole	2025-05-14
2024-12-31	$10,337,752	3,345,551	-33.4%	Shares	Sole	2025-02-14
2024-09-30	$38,678,224	5,023,146	+5.6%	Shares	Sole	2024-11-14
2024-06-30	$40,806,299	4,755,979	+10.1%	Shares	Sole	2024-08-14
2024-03-31	$34,313,114	4,321,551	+1407.4%	Shares	Sole	2024-05-15
2023-12-31	$2,838,270	286,694	—	Shares	Sole	2024-02-14
No filing history on record for this holder in this stock.